Letrozol Teva (Letrozole)

Letrozole blocks the aromatase enzyme, preventing the conversion of androgens to estrogens in peripheral tissues. This leads to a marked reduction in circulating estrogen, depriving estrogen‑dependent breast cancer cells of the hormone they need to grow and proliferate.

The dose of Letrozol Teva is determined by the prescribing physician based on clinical guidelines, patient characteristics, and treatment goals. Healthcare professionals select the appropriate strength and dosing schedule for each individual patient.

Letrozole is contraindicated during pregnancy because it can harm the developing fetus. It is also not recommended while breastfeeding, as it may pass into breast milk and affect the infant. Women of child‑bearing potential should use effective contraception during treatment.

To request Letrozol Teva, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

The primary alternative within the same class is anastrozole, another oral aromatase inhibitor. Both drugs lower estrogen levels, but pharmacokinetic profiles differ slightly; letrozole generally provides a more sustained suppression of estrogen, while anastrozole may have a shorter half‑life. Choice between them depends on physician preference, patient tolerance, and specific clinical scenarios.

Letrozol Teva tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Protect them from excess moisture, heat, and direct sunlight to maintain potency throughout the shelf life.

Letrozol Teva is taken orally, usually once daily, with a glass of water. It can be taken with or without food, but patients should follow the specific instructions provided by their healthcare provider.

Serious risks include severe liver injury, osteoporotic fractures, and thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. Patients should promptly report signs of jaundice, unexplained bone pain, or sudden swelling and shortness of breath to their physician.

Letrozol Teva should not be used in premenopausal women, pregnant or nursing individuals, and patients with known hypersensitivity to letrozole or any component of the formulation. Caution is also advised for those with severe liver impairment or uncontrolled cardiovascular disease.